A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

  • End date
    Apr 23, 2027
  • participants needed
  • sponsor
    CRISPR Therapeutics AG
Updated on 23 May 2022
karnofsky performance status


This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.


The study may enroll approximately 107subjects in total.

Condition Renal Cell Carcinoma
Treatment CTX130
Clinical Study IdentifierNCT04438083
SponsorCRISPR Therapeutics AG
Last Modified on23 May 2022


Yes No Not Sure

Inclusion Criteria

Age ≥18 years and body weight ≥42 kg
Unresectable or metastatic RCC that has exploited standard of care treatment
Karnofsky performance status (KPS) ≥80%
Adequate renal, liver, cardiac, and pulmonary organ function
Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX130 infusion

Exclusion Criteria

Prior treatment with any anti-CD70 targeting agents
Prior treatment with any CAR T cells or any other modified T or natural killer (NK) cells
History of certain central nervous system (CNS), cardiac or pulmonary conditions
Active HIV, hepatitis B virus or hepatitis C virus infection
Previous or concurrent malignancy, except treated with curative approach not requiring systemic therapy and in remission for >12 months, or any other localized malignancy with low risk of developing into metastatic disease
Primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy
Prior solid organ transplantation or bone marrow transplant
Pregnant or breastfeeding females
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note